DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 22, 2000, Isotec, Inc., 3858 Benner Road, Miamisburg, Ohio 45342, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug
Schedule
Cathinone (1235)
I
Methcathinone (1237)
I
N-Ethylamphetamine (1475)
I
N,N-Dimethylamphetamine (1480)
I
Aminorex (1585)
I
Methaqualone (2565)
I
Lysergic acid diethylamide (7315)
I
Tetrahydrocannabinols (7370)
I
Mescaline (7381)
I
2,5-Dimethoxyamphetamine (7396)
I
3,4-methylenedioxyamphetamine (7400)
I
3,4-Methylenedioxy-N-ethylamphetamine (7404)
I
3,4-Methylenedioxymethamphetamine (7405)
I
4-Methoxyamphetamine (7411)
I
Psilocybin (7437)
I
Psilocyn (7438)
I
N-Ethyl-1-phenylcyclohexylamine (7455)
I
Dihydromorphine (9145)
I
Normorphine (9313)
I
Acetylmethadol (9601)
I
Alphacetylmethadol Except Levo-Alphacetylmethadol (9603)
I
Normethadone (9635)
I
3-Methylfentanyl (9813)
I
Amphetamine (1100)
II
Methamphetamine (1105)
II
Methylphenidate (1724)
II
Amobarbital (2125)
II
Pentobarbital (2270)
II
Secobarbital (2315)
II
1-Phenylcyclohexylamine (7460)
II
Phencyclidine (7471)
II
Phenylacetone (8501)
II
1-Piperidinocyclohexanecarbonitrile (8603)
II
Codeine (9050)
II
Dihydrocodeine (9120)
II
Oxycodone (9143)
II
Hydromorphone (9150)
II
Benzoylecgonine (9180)
II
Ethylmorphine (9190)
II
Hydrocodone (9193)
II
Isomethadone (9226)
II
Meperidine (9230)
II
Methadone (9250)
II
Methadone intermediate (9254)
II
Dextropropoxyphene, bulk (non-dosage forms) (9273)
II
Morphine (9300)
II
Thebaine (9333)
II
Levo-Alphacetylmethadol (9648)
II
Oxymorphone (9652)
II
Fentanyl (9801)
II
The firm plans to manufacture small quantities of the listed controlled substances to produce standards for analytical laboratories.
Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than June 5, 2001.
Dated: March 29, 2001.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.